Session Title: GLP-1RAs in Kidney Disease: Mechanisms, Applications in Clinical Practice and the Future
The scientific content of this symposium has been independently developed by ISN. Supported by Novo Nordisk
Session Description:
This symposium will explore the evolving role of GLP-1RAs receptor agonists in kidney disease. Experts will discuss key data from the REMODEL trial, and consider the role of multiparametric imaging and tissue transcriptomics to unravel mechanisms of kidney protection. They will discuss the use of GLP-1RAs receptor agonists in combination with other therapies and applications in clinical practice.
Learning Objectives:
1. Review the mechanistic effects of semaglutide on kidney disease in type 2 diabetes
2. Discuss GLP-1RAs receptor agonists in combination with other therapies and applications in clinical practice
3. Consider the future of GLP-1RAs receptor agonists and other incretin-based therapies for kidney disease
akeda
| Time | Session |
|---|---|
|
08:10
08:20
|
Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL trial
|
|
08:20
08:30
|
Multiparametric Imaging and Tissue Transcriptomics to Unravel Mechanisms of Kidney Protection
|
|
08:30
08:40
|
GLP1s in Combination With Other Therapies and Applications in Clinical Practice
|
|
08:40
08:50
|
The Future of GLP1s and Other Incretin-based Therapies for Kidney Disease
|